Streamlined Preclinical Bioanalytical Strategies: Accelerate your time to IND

Watch the insider session

As drug development timelines continue to compress, the need for streamlined bioanalytical strategies for pharmacokinetic (PK) and immunogenicity (ADA) assessment has never been greater. Optimal platform selection is highly dependent upon therapeutic modality – whether monoclonal antibody, oligonucleotide or antibody-drug conjugate (ADC) – and can significantly impact program timelines. This presentation describes accelerated, modality-specific approaches for PK and ADA assay development that reduce reliance on custom critical reagent generation, enabling more efficient bioanalytical workflows without compromising data quality or regulatory acceptability.

• Tips for selecting the appropriate platform for PK assessment dependent upon drug modality
• How to build PK and ADA assays without custom critical reagents
• Strategies for accelerating sample testing to allow a quicker path to IND